Nasal Drug Delivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops, Nasal Gels, Nasal Powders, and Others), by Container Type (Non-pressurized Containers and Pressurized Containers), by System Type (Multi Dose, Bi Dose, and Unit Dose), by Therapeutics Application (Allergic and Non-allergic Rhinitis, Nasal Congestion, Vaccination, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Nasal cavity is becoming one of the most potential and promising route of drug delivery, owing to its advantages such as bypassing the hepatic first-pass metabolism, and most importantly patient convenience. The nasal drug delivery systems used in the treatment of pain, acute migraine treatment, allergic and non-allergic rhinitis, and nasal congestion brought on by sinusitis, the common cold, or rhinitis. Nasal medication delivery is typically employed when a beginning of action is desired or when other routes of administration prove unsuccessful. Systemic drug administration and needle-free immunization is possible with the help of nasal drug delivery systems. It is possible to use inhalers, droppers, spray pumps, nebulizers, or atomizers to give liquid nasal solutions.
Market Dynamics
Increasing research and development activities for nasal drug delivery systems is expected to drive growth of the global nasal drug delivery system market over the forecast period. For instance, on April 5, 2022, Upperton Pharma Solutions, a U.K. based contract development and manufacturing organization (CDMO) had launched a nasal delivery development platform, UpperNose, for small and mid-sized innovators to access the knowledge and capabilities required for the successful development of nasal dose formulations.
Furthermore, increasing product approvals by regulatory authorities is expected to drive growth of the nasal drug delivery market over the forecast period. For instance, on October 18, 2021, Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company had announced that the U.S. Food and Drug Administration (FDA) had approved TYRVAYA (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray is the first and only nasal spray approved for the treatment of dry eye disease. TYRVAYA Nasal Spray is believed to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook